FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Shares in vaccine developer Vaxcyte soared by over 35% Tuesday after the company unveiled results from a large study testing its experimental pneumococcal shot that analysts described as a best-case ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

The drug is administered via injection and offers long-lasting efficacy, with a monthly maintenance dose required after the ...

Recent FDA approval for new treatments like EBGLYSS and positive trial results bolster its financial outlook amidst executive changes and strategic collaborations in diagnostics and global access ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

The FDA has approved Lilly’s Ebglyss (lebrikizumab-lbkz) for the treatment of moderate to severe atopic dermatitis in adults ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...